Connect with us

Technology

Cumulus Neuroscience to Join Bio-Hermes 2 Study with Funding from the Innovate UK Small Business Research Initiative (SBRI) Dementia Mission Project

Published

2 years ago

on

Funded by a nearly £1.2M (~$1.5M USD) award, this research will enable ongoing validation of AccelADx™, a breakthrough screening test for early detection of Alzheimer’s dementia.

BELFAST, Northern Ireland and CAMBRIDGE, Mass., July 11, 2024 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, today announced receipt of funding from Innovate UK, the UK’s innovation agency, which drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas.

Funded by Innovate UK’s Small Business Research Initiative (SBRI), this award is focused on enabling organisations with select novel biomarkers to be evaluated as part of the Global Alzheimer’s Platform Foundation (GAP) Bio-Hermes 2 Study. Cumulus will deploy AccelADx in the study, a novel, AI-enabled screening test that detects small, subtle changes in brain waves associated with memory recall. Bio-Hermes 2, which aims to generate data to accelerate the adoption and effective use of biomarkers in the study of Alzheimer’s disease, will investigate the relationship of novel biomarkers to the current gold standard diagnosis across an ethnically diverse population of 1,000 participants in the United States, Canada, and Europe. The data collected in Bio-Hermes 2 will provide a rich dataset on the extent to which digital and other biomarkers can substitute for more labor-intensive clinical exams and expensive positron emission tomography (PET) scans. Importantly, Cumulus will gain access to the full Bio-Hermes 2 dataset and regulatory-standard data to enable subsequent submissions.

“The diagnosis of Alzheimer’s dementia requires detection of changes in brain biology and memory function. While blood tests are emerging to assess biology, physicians still lack accurate tools for detecting changes in cognition and memory, which directly drive loss of independence and reduced quality of life for patients and their caregivers,” said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. “Existing written and computerised cognitive tests can yield false results if patients are anxious or do not understand the instructions. Our goal is to help patients and physicians more directly with the AccelADx screening test, which is uniquely scalable, complementary to protein markers, and specific to Alzheimer’s disease. This Innovate UK SBRI award will allow us to validate how well AccelADx works in a large and diverse group of patients, providing critical data to support regulatory approval.”

The Cumulus NeuLogiq™ Platform – which includes a first-in-class FDA-cleared and UKCA-marked dry electrode electroencephalogram (EEG) headset – can track the integrity and connectivity of brain networks. The headset synchronises with tablet-based assessments across multiple domains of brain function for use in-clinic or remotely at-home, allowing for an increased ease-of-use for patients, caregivers, and clinical teams.

“Alzheimer’s dementia is a devastating disease for patients and their families, directly affecting almost 60 million people today. This is a global problem that requires a global solution,” said Dr. George Stothart, senior lecturer, Department of Psychology, University of Bath, inventor of AccelADx, and Research Fellow at Cumulus. “In many cases, symptoms appear very gradually and can be difficult to detect during the early stages of disease. As a result, many patients miss the opportunity to fully benefit from newer treatments focused on slowing disease progression. Quicker, more accurate ways to diagnose dementia are greatly needed so that patients can get treatments earlier and families have an opportunity to plan for the future. We believe AccelADx has the potential to address this substantial unmet need.”

Alzheimer’s is a progressive disease that affects brain function, memory, and other cognitive abilities. It is the most common cause of dementia, affecting millions of people worldwide. Symptoms usually develop slowly and worsen over time, including memory loss, confusion, mood swings, changes in behavior and personality, and difficulty with language and communication. Currently, there is no known cure for Alzheimer’s. Today, earlier diagnosis can enable patients to make lifestyle changes, including exercising and decreasing alcohol consumption, both of which have been shown to slow disease progression. In the future, having the ability to diagnose patients earlier may expedite enrollment in clinical studies and the identification of new treatments.

Cumulus supports precision in CNS clinical trials for its industry partners by enabling remote monitoring of patients across multiple domains of brain function. To learn more, visit www.cumulusneuro.com.

About Cumulus Neuroscience
With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing NeuLogiq™, an AI-based, multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinical trials and patient care. Designed for and with 10 of the world’s leading pharma companies, the platform enables decentralized trials, and is already making a difference in the development of therapies for Alzheimer’s Disease, depression, and schizophrenia.

Designed to provide an industry-wide standard for real-world measurement of disease progression, Cumulus combines patented technology, in-house expertise, and key industry partnerships to capture large amounts of real-world, clinical data repeated over time, across multiple behavioral and physiological domains in the patient’s home – all with an EEG headset synced to a novel, tablet-based neuro-assessment platform. Together with machine learning (ML) analytics and the world’s largest database of annotated, longitudinal, neurofunctional data, Cumulus simplifies and improves the robustness of neuroscience clinical trials to provide the best and most cost-effective assessment of CNS treatment outcomes.

The Company is supported by highly experienced specialized investors, DDF/SV Health Investors, LifeArc and Future Fund, and a world-class Scientific and Technical Advisory Board.

FOR MORE INFORMATION
Julie Dietel
FINN Partners for Cumulus
julie.dietel@finnpartners.com
Tel: 978.502.7705

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cumulus-neuroscience-to-join-bio-hermes-2-study-with-funding-from-the-innovate-uk-small-business-research-initiative-sbri-dementia-mission-project-302195043.html

SOURCE Cumulus Neuroscience

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

POVADDO LAUNCHES NEW RESEARCH SERVICE GIVING ORGANIZATIONS DIRECT ACCESS TO INSIGHTS FROM PUBLIC POLICY PROFESSIONALS IN THE U.S. AND EUROPE

Published

54 minutes ago

on

May 4, 2026

By

The Povaddo Panel Omnibus introduces a new shared-survey format that makes high-quality policy professional insights accessible at a fraction of the cost of a bespoke study

ST. LOUIS, May 3, 2026 /PRNewswire/ — Povaddo, a leading provider of public opinion and policy elite research, today announced the launch of the Povaddo Panel Omnibus — a new research service that gives companies and organizations an efficient, cost-effective way to access public policy professional insights across the United States and Europe. Unlike Povaddo’s custom research offerings, the omnibus format allows multiple organizations to share survey space, significantly reducing cost while maintaining the same access to high-quality insights.

Launched in 2018, the Povaddo Panel was built to meet the growing demand for research insights from individuals who shape, influence, and analyze public policy as part of their daily work. Over the past eight years, the panel has grown to nearly 5,000 public policy professionals worldwide, including more than 2,000 in the United States. Many panelists are former elected officials, including former Members of Congress. Each panelist is individually verified to ensure both authenticity and quality.

The 2026 Povaddo Panel Omnibus schedule includes three waves, with the first launching on June 15. Companies and organizations can field questions among 200 U.S. public policy professionals and/or 200 European public policy professionals, with results delivered within two weeks. Pricing begins at $4,500 for a five-question package among one audience, or $8,000 for both the U.S. and European audiences. Each omnibus package includes:

Question consultation to ensure clarity and effectivenessData collection among the selected audienceTopline results for the total sample and key subgroups

To learn more, reserve space in an upcoming wave, or submit questions, please visit the “Omnibus” section of Povaddo’s website or email omnibus@povaddo.com.

“Companies and organizations that want to understand what public policy professionals think—whether about their brand or an issue they are facing—now have a new and more streamlined way to do so. While organizations have long been able to commission custom research through Povaddo, our new omnibus survey among public policy professionals fills an important need in the research marketplace,” said Brooke Hayes, Executive Vice President of Povaddo, who oversees the Povaddo Panel and the firm’s new omnibus research service.

“The organizations that navigate complex policy environments most successfully are the ones that understand how the policy community thinks. The Povaddo Panel Omnibus makes that kind of insight accessible and actionable for any organization that needs it,” said William Stewart, President and Founder of Povaddo. “What’s more, we know many senior management teams are keen to measure their organizations’ reputation among this elite audience.”

The Povaddo Panel Omnibus launches alongside Povaddo’s most recent thought leadership study, which illustrates the kind of distinctive insights the panel is uniquely positioned to deliver. Povaddo’s 2026 survey of public policy professionals in the U.S. and Europe examines attitudes toward artificial intelligence, including AI regulation, labor market impact, misinformation risk, and the broader existential concerns of the policy community. A high-level summary of select key findings is available on Povaddo’s website, and the complete 38-page report is available for purchase at $500.

About Povaddo: Povaddo specializes in public opinion and policy elite research. Founded in 2009, Povaddo is recognized as a trusted advisor to top-tier organizations that are navigating complex issues management, strategic communications, corporate reputation, and business transformation challenges. Povaddo’s expertise spans external affairs, corporate affairs, public affairs, government affairs, regulatory affairs, scientific affairs, corporate communications, and business planning and strategy. For more information, please visit www.povaddo.com.

Inquiries:

Brooke Hayes
+1 (855) 768-2336
hayes@povaddo.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/povaddo-launches-new-research-service-giving-organizations-direct-access-to-insights-from-public-policy-professionals-in-the-us-and-europe-302760478.html

SOURCE POVADDO LLC

Continue Reading

Technology

Tianma Highlighting Micro-LED HUD, Ultra-High-Refresh AMOLED, and Glasses-Free 3D Medical Display at Display Week 2026

Published

54 minutes ago

on

May 4, 2026

By

Tianma, a leading global manufacturer of flat panel displays, will showcase its latest display innovations at SID Display Week 2026, taking place May 5–7 at the Los Angeles Convention Center. At Booth 805, South Hall, Tianma will highlight three key technology demonstrations spanning automotive, mobile, and medical applications: a Micro-LED head-up display (HUD) designed for extreme brightness and transparency, an ultra-high-refresh-rate AMOLED display engineered for next-generation mobile performance, and a glasses-free 3D medical display enabling real-time 2D/3D visualization.

CHINO, Calif., May 3, 2026 /PRNewswire-PRWeb/ — Tianma, a leading global manufacturer of flat panel displays, will showcase its latest display innovations at SID Display Week 2026, taking place May 5–7 at the Los Angeles Convention Center.

At Booth 805, South Hall, Tianma will highlight three key technology demonstrations spanning automotive, mobile, and medical applications: a Micro-LED head-up display (HUD) designed for extreme brightness and transparency, an ultra-high-refresh-rate AMOLED display engineered for next-generation mobile performance, and a glasses-free 3D medical display enabling real-time 2D/3D visualization.

This year, at the annual Business Conference on Monday, May 4, Tianma’s Jun Chen, Ph.D., Senior Manager, Automotive Market Development, will be a featured panelist during the Automotive Forum. In addition, Tianma has entered several new cutting-edge products and technologies into SID’s annual People’s Choice Awards competition, honoring the best products at Display Week.

KEY TECHNOLOGY HIGHLIGHTS

Micro-LED IRIS HUD for Next-Generation Automotive Displays

Tianma’s 12-inch Micro-LED IRIS HUD is engineered to address one of the most critical challenges in automotive display design: maintaining visibility under all lighting conditions without compromising driver awareness.

Delivering peak brightness exceeding 120,000 nits, the display remains clearly visible even in direct sunlight. Its Micro-LED architecture enables an ultra-thin optical engine (approximately 2 mm), while a transparent front-window design eliminates the need for black masking layers — preserving the driver’s field of view and supporting more advanced, integrated cockpit designs.

Ultra-High-Refresh AMOLED for Next-Generation Mobile Performance

In mobile display technology, Tianma will showcase a 6.32-inch AMOLED display with a 240Hz refresh rate, designed to overcome the traditional trade-offs between speed and image accuracy. The display incorporates a dual-track pixel driving architecture, separating data writing and threshold compensation to maintain stable, precise pixel control at high refresh rates. This approach significantly reduces motion artifacts while preserving low-gray detail, enabling smoother visuals and improved image stability for high-performance mobile applications.

Glasses-Free 3D Medical Display with Multi-Region 2D/3D Switching

For advanced professional applications, Tianma will present a 27-inch 4K medical-grade glasses-free 3D display, introducing multi-region 2D/3D switching capabilities. Unlike conventional systems limited to full-screen 3D, this display enables simultaneous presentation of 2D and 3D content, with seamless, real-time switching between modes. The system integrates low-latency eye tracking and real-time rendering, making it well suited for medical environments where precision, flexibility, and sterile operation are critical.

BROAD PORTFOLIO OF DISPLAY INNOVATIONS

In addition to these featured technologies, Tianma will present a wide range of display solutions across automotive, consumer, and professional applications.

In automotive, Tianma will showcase a transparent Micro-LED tiling display with over 60% transparency and a scalable, modular design, along with a 43.7-inch ultra-wide IRIS HUD featuring high brightness and curved integration for immersive cockpit environments.

In consumer electronics, Tianma will highlight its latest AMOLED innovations, including SLOD and U11 architectures designed to improve efficiency, brightness, and device lifetime, as well as a foldable AMOLED prototype engineered to reduce crease visibility and improve durability.

For IT applications, Tianma will demonstrate a 27-inch QHD Oxide TFT LCD with a native 610Hz refresh rate, setting a new benchmark for ultra-high-frame-rate displays.

In professional and industrial applications, Tianma will also feature an adaptive refresh Oxide display (20–144Hz) designed to balance high performance with power efficiency.

Advancing Display Innovation Across Applications

Together, these demonstrations reflect Tianma’s continued investment in Micro-LED, AMOLED, and advanced LCD technologies, enabling new levels of performance, efficiency, and integration across automotive, consumer, and professional markets. More information about the innovative new display solutions being displayed by Tianma is available at Booth 805 at Display Week and in the Tianma press kits, accessible online at usa.tianma.com/press Visit usa.tianma.com for more details.

About Tianma America, Inc.

Tianma America delivers advanced display solutions for the Americas, leveraging the global resources and innovation of the Tianma Group. Our expertise spans small to medium-size displays for a wide range of applications, including automotive, industrial, medical, consumer electronics, and emerging technologies.

As part of the Tianma Group, we combine world-class R&D with manufacturing capabilities across China and Japan to offer cutting-edge technologies such as TFT, LTPS, Oxide-TFT, AMOLED, flexible and transparent displays, and integrated touch solutions.

Through a strong network of distributors and partners, Tianma America provides complete display module solutions that meet the highest standards of quality and performance.

Specifications and pricing are subject to change without notice.

Media Contact

Dale Maunu, Tianma America, Inc., 1 408-313-5642, Dale.Maunu@Tianma.com, usa.tianma.com

Bill Maurer, Macrovision, 1 215-327-8109, bill@macrovis.com, macrovision.com

View original content to download multimedia:https://www.prweb.com/releases/tianma-highlighting-micro-led-hud-ultra-high-refresh-amoled-and-glasses-free-3d-medical-display-at-display-week-2026-302760839.html

SOURCE Tianma America, Inc.

Continue Reading

Technology

FranklinWH Introduces Enhanced 15 kWh aPower in Australia and New Zealand

Published

3 hours ago

on

May 3, 2026

By

Expansion comes as policy shifts and rising power costs accelerate demand for residential energy storage

SYDNEY, May 4, 2026 /PRNewswire/ — FranklinWH, a leading provider of whole-home energy management and battery storage solutions, today announced the launch of its enhanced 15 kWh aPower battery in Australia and New Zealand, as demand for residential energy storage continues to grow, driven by evolving policy settings and increasing interest in energy independence.

The updated aPower builds on the company’s established platform, increasing usable capacity from 13.6 kWh to 15 kWh and raising warrantied throughput from 43 MWh to 60 MWh, an increase of 40 percent. These updates deliver more usable energy over the life of the system while maintaining the same footprint and price.

“The energy landscape is shifting quickly, and more homeowners are thinking beyond the upfront specs to what really pays off over time,” said Steve Ruskin, General Manager of FranklinWH Australia. “This upgrade is about delivering more performance over the life of the system, more usable energy, greater throughput, while staying true to our ‘buy once, buy right’ philosophy.”

The increase in warrantied throughput translates into savings for homeowners. Based on typical usage patterns and an electricity rate of A$0.35 per kilowatt-hour, the additional throughput may represent up to approximately A$5,950 in value over the lifetime of the system. The increase in usable capacity also improves energy density, lowering the effective cost per kilowatt-hour and supporting more efficient use of stored energy.

The 15 kWh configuration also aligns with current and upcoming policy frameworks benefitting residential battery adoption. This includes the updated Cheaper Home Batteries Program, with changes coming into effect for Australian homeowners from 1 May, 2026, helping households maximise value as incentives continue to evolve.

As the residential battery market expands, FranklinWH continues to focus on reliability and system performance. The aPower incorporates design elements to support durability, including structural reinforcement to reduce cell stress over time, per-cell temperature monitoring, and the separation of the battery pack and control systems to maintain reliable performance.

“We believe performance should be measured over years, not just at installation,” Ruskin added. “We focus on building systems that deliver consistent, reliable results over time. That long-term perspective is what ultimately defines value for homeowners.”

The aPower is designed to operate as part of the FranklinWH System, an integrated home energy management platform that coordinates energy generation, storage, and consumption. The system is designed to optimise multiple energy inputs, provide reliable backup power, and support more efficient and independent energy use at the household level.

About FranklinWH

FranklinWH Energy Storage is the manufacturer of the FranklinWH System. FranklinWH is a market-oriented, research-driven company focused on next-generation residential energy management and storage solutions. Located in Macquarie Park, Sydney with a global head office in the San Francisco Bay Area, FranklinWH’s team has decades of experience in energy systems, from design, through manufacturing, to sales and installation. FranklinWH is AVL-listed with multiple financial institutions.

Contact: Media@franklinwh.com

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/franklinwh-introduces-enhanced-15-kwh-apower-in-australia-and-new-zealand-302759086.html

SOURCE FranklinWH Australia Pty Ltd

Continue Reading

Trending